Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAIR: Farletuzumab in Stage IV Lung Adenocarcinoma
NCT01218516Phase 2Completed
- Sponsor
- Morphotek
- Start
- Jun 2011
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in lung adenocarcinoma comparing Farletuzumab Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival up to 28 months. Started Jun 2011; status: completed.
02
Drugs
farletuzumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01218516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01218516.